IFN-γ + CIK cells + Tcm cells + CAR T cells

This is a multi-component investigational cell therapy combining four distinct immunotherapeutic modalities: - **Interferon gamma (IFN-γ):** A cytokine that activates immune responses, particularly enhancing the cytotoxic activity of immune effector cells. - **Cytokine-induced killer (CIK) cells:** Ex vivo expanded immune effector lymphocytes with both NK cell-like and T-cell properties, capable of non-MHC-restricted tumor killing. - **Central memory T (Tcm) cells:** A subset of memory T lymphocytes with high proliferative potential and long-term persistence, contributing to sustained antitumor immunity. - **Chimeric antigen receptor (CAR) T-cells:** Genetically engineered autologous or allogeneic T-cells expressing synthetic receptors targeting specific tumor antigens for direct cancer cell lysis[1][2][7]. The combination aims to leverage the complementary mechanisms of each component—cytokine activation, broad cytotoxicity, durable memory response, and targeted antigen-specific killing—to enhance overall antitumor efficacy. This approach is under investigation for hematologic malignancies and potentially solid tumors.

Other names

IFN-gamma plus CIK cells plus Tcm cells plus CAR T cellsIFN-γ and CIK and Tcm and CAR-T combination